Pelthos Therapeutics to merge with Castle Creek Biosciences

 

Castle Creek holders to own about 32.5% of combined company

• Castle Creek shareholders to receive 5.2 million Pelthos shares, representing about 32.5% of the combined company.
• Transaction includes additional contingent milestone considerations for Castle Creek shareholders following completion of the merger.
• Merger adds late-stage gene therapy candidate D-Fi to Pelthos Therapeutics' dermatology portfolio.

https://finviz.com/stock?t=PTHS&p=d